Head-to-head evidence
ANPD001 vs iPS-NSC cells
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopaminergic neuron replacement · full Parkinson's Disease pipeline
ANPD001
Developed by Aspen Neuroscience
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT06344026 (registry estimate)
iPS-NSC cells
Developed by Allife Medical Science and Technology
NCT03815071 · Phase 1 · status unknown
This is a small, single-arm, unblinded study of 10 participants with no control group, designed to check safety rather than test efficacy against a comparator, and results have not yet been posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ANPD001's landscape · iPS-NSC cells's landscape